BioSig Technologies Q4 2024 Earnings Net Loss Narrows 82.1%

BioSig Technologies (BSGM) reported its fiscal 2024 Q4 earnings on May 19th, 2025. The company announced a net loss reduction from $6.13 million to $1.10 million, achieving an 82.1% improvement. Despite deepening losses per share, BioSig maintained its revenue growth trajectory, increasing total revenue by 8.3% year-over-year to $13,000. Looking ahead, BioSig projects an EPS of -$0.07 for the upcoming quarter, with revenue expected to remain stable. The company remains committed to enhancing operational efficiency and reducing costs to improve financial outcomes.

Revenue

BioSig Technologies reported a revenue increase of 8.3% for the fourth quarter of 2024, reaching $13,000, compared to $12,000 in the same quarter of the previous year.

Earnings/Net Income

BioSig Technologies managed to narrow its net loss significantly, reporting $-1.10 million in Q4 2024 versus a $-6.13 million loss in Q4 2023. While the EPS loss remained at $0.07 per share, a wider loss by 9.8%, the significant reduction in net loss reflects progress in addressing financial headwinds.

Price Action

The stock price of BioSig Technologies edged up 1.97% during the latest trading day, surged 30.50% during the most recent full trading week, and increased 390.52% month-to-date.

Post Earnings Price Action Review

The strategy of buying BioSig Technologies shares after a revenue increase and holding for 30 days has proven effective over the past five years, delivering returns of 141.12% against a benchmark loss of -2.26%. This approach's compound annual growth rate (CAGR) was 382.09%, showcasing its potential for generating substantial returns despite a high volatility profile, evidenced by a 170.12% standard deviation. The strategy's maximum drawdown of -76.18% and Sharpe ratio of 2.25 highlight the substantial risk involved, yet it consistently outperformed market expectations. Overall, while the strategy demonstrated robust growth, investors should remain aware of its inherent risks and volatility.

CEO Commentary

Anthony Amato, CEO of BioSig Technologies, expressed optimism regarding the company's recent performance, highlighting the successful launch of the PURE EP™ Platform as a key growth driver. He acknowledged ongoing challenges in the competitive medical technology landscape but emphasized the company’s commitment to innovation and strategic partnerships that enhance market positioning. Amato noted that the latest results reflect progress towards operational goals, and he is confident in the potential to improve financial stability while focusing on advancing the company’s offerings and expanding its market reach.

Guidance

BioSig Technologies projects an EPS of -$0.07 for the upcoming quarter, while revenue is anticipated to remain around $13,000, reflecting the ongoing transition in their business model. The leadership expects to enhance operational efficiency and reduce costs, positioning the company for improved financial outcomes as they advance their product development and marketing strategies.

Additional News

BioSig Technologies recently announced a strategic merger with Streamex Exchange, aimed at creating a publicly listed real-world asset tokenization company. Streamex will initially acquire a 19.9% stake in BioSig, potentially expanding to 75% contingent upon share conversions. This merger represents a transformative opportunity for BioSig, expanding its market reach and enhancing capabilities. Additionally, BioSig regained full compliance with Nasdaq requirements, ensuring continued listing on the Nasdaq Capital Market. With structural changes in leadership, BioSig appointed CEO Anthony Amato and announced new board members to steer the company's next phase of growth.